NYSE:PFEPharmaceuticals
How Pfizer’s Lyme Vaccine Trial Results Could Shape Pipeline Renewal for Pfizer (PFE) Investors
Pfizer and Valneva recently reported that their investigational 6‑valent OspA-based Lyme disease vaccine achieved more than 70% efficacy in a completed Phase 3 VALOR trial, with a favorable safety profile, and plan to submit the data to regulators despite the study missing its primary statistical criterion due to fewer Lyme cases than expected.
This progress in Lyme disease prevention, where no human vaccines are currently approved, highlights how Pfizer’s vaccines pipeline could help...